Frontlight ResearchEarly access
Haemophilia trials in Sweden
4 of 8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleSafety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- Where
- Malmö
- Age
- 18 years and over
- People
- 173 worldwide
- Run by
- Pfizer
See details and how to joinNCT05568719 - Phase 3Taking peopleA Non-Investigational Product, Multi-Center Cohort Study to Describe Long-Term Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec
- Where
- Malmö
- Age
- 18 years to 64 years
- People
- 32 worldwide
- Run by
- Pfizer Inc.
See details and how to join2025-523660-21-00 - Phase 1Active, not recruitingA Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
- Where
- Malmo, Solna
- Age
- 18 years to 64 years
- People
- 30 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07220564 · EU 2025-520490-38-00 - Phase 1Not yet taking people in SwedenThis is a first in human study, in patients with severe bleeding disorder (hemophilia A), who has developed inhibitory antibodies against coagulation factor VIII.The aim is to study the safety and efficacy of dendritic cells, originating from the patient itself. The dendritic cells has been loaded with coagulation factor VIII for an improved immunological tolerance. (TOLER8)
- Where
- Lund
- Age
- 18 years to 64 years
- People
- 4 worldwide
- Run by
- Cell4Cure AB
See details and how to join2022-502030-12-01